120 related articles for article (PubMed ID: 34023294)
1. KDM2B promotes cell viability by enhancing DNA damage response in canine hemangiosarcoma.
Gulay KCM; Aoshima K; Shibata Y; Yasui H; Yan Q; Kobayashi A; Kimura T
J Genet Genomics; 2021 Jul; 48(7):618-630. PubMed ID: 34023294
[TBL] [Abstract][Full Text] [Related]
2. The expression of histone lysine demethylase 2B in canine hemangiosarcoma is associated with disease progression.
Gulay KCM; Aoshima K; Kim S; Kitaguchi R; Kobayashi A; Kimura T
Vet Comp Oncol; 2022 Jun; 20(2):529-534. PubMed ID: 34927338
[TBL] [Abstract][Full Text] [Related]
3. High drug efflux pump capacity and low DNA damage response induce doxorubicin resistance in canine hemangiosarcoma cell lines.
Morita A; Aoshima K; Gulay KCM; Onishi S; Shibata Y; Yasui H; Kobayashi A; Kimura T
Res Vet Sci; 2019 Dec; 127():1-10. PubMed ID: 31648115
[TBL] [Abstract][Full Text] [Related]
4. Hemangiosarcoma cells induce M2 polarization and PD-L1 expression in macrophages.
Gulay KCM; Aoshima K; Maekawa N; Suzuki T; Konnai S; Kobayashi A; Kimura T
Sci Rep; 2022 Feb; 12(1):2124. PubMed ID: 35136176
[TBL] [Abstract][Full Text] [Related]
5. Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Kuang Y; Lu F; Guo J; Xu H; Wang Q; Xu C; Zeng L; Yi S
Onco Targets Ther; 2017; 10():3131-3144. PubMed ID: 28706445
[TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor-related apoptosis-inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitro.
Goto M; Owaki K; Hirata A; Yanai T; Sakai H
Vet Comp Oncol; 2019 Sep; 17(3):285-297. PubMed ID: 30767429
[TBL] [Abstract][Full Text] [Related]
7. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.
Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM
Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249
[TBL] [Abstract][Full Text] [Related]
8. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.
Kurt IC; Sur I; Kaya E; Cingoz A; Kazancioglu S; Kahya Z; Toparlak OD; Senbabaoglu F; Kaya Z; Ozyerli E; Karahüseyinoglu S; Lack NA; Gümüs ZH; Onder TT; Bagci-Onder T
Cell Death Dis; 2017 Jun; 8(6):e2897. PubMed ID: 28661478
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-214 Promotes Apoptosis in Canine Hemangiosarcoma by Targeting the COP1-p53 Axis.
Heishima K; Mori T; Sakai H; Sugito N; Murakami M; Yamada N; Akao Y; Maruo K
PLoS One; 2015; 10(9):e0137361. PubMed ID: 26335793
[TBL] [Abstract][Full Text] [Related]
10. KDM2B is a histone H3K79 demethylase and induces transcriptional repression via sirtuin-1-mediated chromatin silencing.
Kang JY; Kim JY; Kim KB; Park JW; Cho H; Hahm JY; Chae YC; Kim D; Kook H; Rhee S; Ha NC; Seo SB
FASEB J; 2018 Oct; 32(10):5737-5750. PubMed ID: 29763382
[TBL] [Abstract][Full Text] [Related]
11. Tenovin-6 induces the SIRT-independent cell growth suppression and blocks autophagy flux in canine hemangiosarcoma cell lines.
Igase M; Fujiki N; Shibutani S; Sakai H; Noguchi S; Nemoto Y; Mizuno T
Exp Cell Res; 2020 Mar; 388(1):111810. PubMed ID: 31891684
[TBL] [Abstract][Full Text] [Related]
12. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
Adachi M; Hoshino Y; Izumi Y; Sakai H; Takagi S
Can J Vet Res; 2016 Jul; 80(3):209-16. PubMed ID: 27408334
[TBL] [Abstract][Full Text] [Related]
13. The antischistosomal potential of GSK-J4, an H3K27 demethylase inhibitor: insights from molecular modeling, transcriptomics and in vitro assays.
Lobo-Silva J; Cabral FJ; Amaral MS; Miyasato PA; de Freitas RP; Pereira ASA; Khouri MI; Barbosa MMF; Ramos PIP; Leite LCC; Asojo OA; Nakano E; Verjovski-Almeida S; Farias LP
Parasit Vectors; 2020 Mar; 13(1):140. PubMed ID: 32178714
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
15. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
Pyuen AA; Meuten T; Rose BJ; Thamm DH
PLoS One; 2018; 13(7):e0200634. PubMed ID: 30011343
[TBL] [Abstract][Full Text] [Related]
16. Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Staberg M; Rasmussen RD; Michaelsen SR; Pedersen H; Jensen KE; Villingshøj M; Skjoth-Rasmussen J; Brennum J; Vitting-Seerup K; Poulsen HS; Hamerlik P
Mol Oncol; 2018 Mar; 12(3):406-420. PubMed ID: 29360266
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma.
Fukumoto S; Saida K; Sakai H; Ueno H; Iwano H; Uchide T
Life Sci; 2016 Aug; 159():55-60. PubMed ID: 26835989
[TBL] [Abstract][Full Text] [Related]
18. Association of Sphingosine-1-phosphate (S1P)/S1P Receptor-1 Pathway with Cell Proliferation and Survival in Canine Hemangiosarcoma.
Rodriguez AM; Graef AJ; LeVine DN; Cohen IR; Modiano JF; Kim JH
J Vet Intern Med; 2015; 29(4):1088-97. PubMed ID: 26118793
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment.
Kim JH; Frantz AM; Anderson KL; Graef AJ; Scott MC; Robinson S; Sharkey LC; O Brien TD; Dickerson EB; Modiano JF
Exp Cell Res; 2014 Apr; 323(1):155-164. PubMed ID: 24582862
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells.
Sui A; Xu Y; Li Y; Hu Q; Wang Z; Zhang H; Yang J; Guo X; Zhao W
Oncotarget; 2017 Sep; 8(40):68591-68598. PubMed ID: 28978140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
